Shibin Zhou

List of Publications by Citations

Source: https://exaly.com/author-pdf/8110510/shibin-zhou-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16,728 33 21 37 g-index h-index citations papers 6.17 21,080 17.6 37 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
33	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015 , 372, 2509-20	59.2	5560
32	Cancer genome landscapes. <i>Science</i> , 2013 , 339, 1546-58	33.3	5058
31	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017 , 357, 409	-43333	3274
30	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018 , 359, 926-930	33.3	1204
29	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 11774-9	11.5	426
28	Tumour-targeting bacteria engineered to fight cancer. <i>Nature Reviews Cancer</i> , 2018 , 18, 727-743	31.3	196
27	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020 , 369,	33.3	149
26	Disruption of aßelf-amplifying catecholamine loop reduces cytokine release syndrome. <i>Nature</i> , 2018 , 564, 273-277	50.4	116
25	Applications of liquid biopsies for cancer. Science Translational Medicine, 2019, 11,	17.5	97
24	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. <i>ACS Nano</i> , 2015 , 9, 6861-71	16.7	89
23	Preventing cytokine storm syndrome in COVID-19 using El adrenergic receptor antagonists. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3345-3347	15.9	69
22	Targeting a neoantigen derived from a common mutation. Science, 2021, 371,	33.3	68
21	A diaCEST MRI approach for monitoring liposomal accumulation in tumors. <i>Journal of Controlled Release</i> , 2014 , 180, 51-9	11.7	47
20	Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. <i>Oncotarget</i> , 2015 , 6, 5536-46	3.3	46
19	Bispecific antibodies targeting mutant neoantigens. Science Immunology, 2021, 6,	28	42
18	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021 , 596, 126-132	50.4	40
17	CEST theranostics: label-free MR imaging of anticancer drugs. <i>Oncotarget</i> , 2016 , 7, 6369-78	3.3	36

LIST OF PUBLICATIONS

16	A robust approach to enhance tumor-selective accumulation of nanoparticles. <i>Oncotarget</i> , 2011 , 2, 59-0	58 .3	35
15	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 9967	- 72 1.5	27
14	Characterization of tumor vascular permeability using natural dextrans and CEST MRI. <i>Magnetic Resonance in Medicine</i> , 2018 , 79, 1001-1009	4.4	26
13	Direct Detection and Quantification of Neoantigens. Cancer Immunology Research, 2019, 7, 1748-1754	12.5	21
12	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	19
11	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	14
10	CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. <i>Magnetic Resonance in Medicine</i> , 2019 , 82, 1471-1479	4.4	12
9	CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019 , 9, 1579-1591	3.6	11
8	TCR Ithain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	10
7	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021 , 2, 487-497	15.4	10
6	An engineered antibody fragment targeting mutant Etatenin via major histocompatibility complex I neoantigen presentation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 19322-19334	5.4	8
5	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. <i>ELife</i> , 2021 , 10,	8.9	7
4	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021 , 12, 5271	17.4	5
3	Combination therapy with bacteria and angiogenesis inhibitors: strangling cancer without mercy. <i>Cancer Biology and Therapy</i> , 2005 , 4, 846-7	4.6	3
2	Combination bacteriolytic cancer therapy: Attacking cancer from inside out. <i>Discovery Medicine</i> , 2004 , 4, 33-7	2.5	2
1	TCR-mimic bispecific antibodies to target the HIV-1 reservoir <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2123406119	11.5	O